Peer-reviewed veterinary case report
Robenacoxib pain and inflammation relief dosing in cats
By Giraudel, J M et al.·Published in Journal of veterinary pharmacology and therapeutics·2009·Ecole Nationale Vé, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib.
- Species:
- cat
Plain-English summary
A group of 10 cats with paw inflammation were treated with a new pain relief medication called robenacoxib to see how well it worked for reducing pain and swelling. The cats received a dose of 2 mg/kg of the medication under the skin, and their lameness and movement were closely monitored. The results showed that robenacoxib effectively reduced inflammation and improved the cats' ability to move comfortably. This study helps veterinarians determine the best dosage for using robenacoxib in cats with similar issues.
People also search for: cat paw inflammation treatment · robenacoxib for cats · cat pain relief medication
Abstract
This study investigated the analgesic, anti-inflammatory and antipyretic efficacy of the new COX-2 selective inhibitor robenacoxib in the cat and established pharmacodynamic (PD) parameters for these effects. Robenacoxib, at a dosage of 2 mg/kg administered subcutaneously, was evaluated in a kaolin-induced paw inflammation model in 10 cats, using both clinically relevant endpoints (lameness scoring, locomotion tests) and other indicators of inflammation (body and skin temperature, thermal pain threshold) to establish its pharmacological profile. A pharmacokinetic/pharmacodynamic (PK/PD) modelling approach, based on indirect response models, was used to describe the time course and magnitude of the responses to robenacoxib. All endpoints demonstrated good responsiveness to robenacoxib administration and both the magnitude and time courses of responses were well described by the indirect pharmacodynamic response models. Pharmacokinetic and clinically relevant pharmacodynamic parameters were used to simulate dosage regimens that will assist the planning of clinical trials and the selection of an optimal dosage regimen for robenacoxib in the cat.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19161452/